AndreaBozzo/ceres-open-data-index huggingface dataset:
Unpredicted spontaneous extrusion of a renal calculus in an adult male with spina bifida and paraplegia: report of a misdiagnosis. Measures to be taken to reduce urological errors in spinal cord injury patients

Background
          A delay in diagnosis or a misdiagnosis may occur in patients with spinal cord injury (SCI) or spinal bifida as typical symptoms of a clinical condition may be absent because of their neurological impairment.
        
        
          Case presentation
          A 29-year old male, who was born with spina bifida and hydrocephalus, became unwell and developed a swelling and large red mark in his left loin eighteen months ago. Pyonephrosis or perinephric abscess was suspected. X-ray of the abdomen showed left-sided staghorn calculus. Since ultrasound scan showed no features of pyonephrosis or perinephric abscess, he was prescribed a prolonged course of antibiotics for infection presumed to arise from the site of metal implant in spine. He developed a discharging sinus, following which the loin swelling and red mark subsided. About three months ago, he again developed a red mark and minimal swelling in the left loin. Ultrasound scan detected no abnormality in the renal or perinephric region. Therefore, the red mark and swelling were attributed to pressure from the backrest of his chair. Five weeks later, the swelling in the left loin burst open and a large stone was extruded spontaneously. An X-ray of the abdomen showed that he had extruded the central portion of the staghorn calculus from left kidney. With hindsight, the extruded renal calculus could be seen lying in the subcutaneous tissue of left loin lateral to the 10th rib in the X-ray of abdomen, which was taken when he presented with red mark and minimal swelling.
        
        
          Conclusion
          This case illustrates how mistakes in diagnosis could occur in spinal cord injury patients, and highlights the need for corrective measures to reduce urological errors in these patients. Voluntary reporting of urological errors is recommended to facilitate learning from our mistakes. In the patients who have marked spinal curvature, ultrasonography of kidneys and perinephric region may not be entirely reliable. As clinical symptoms and signs may be non-specific in SCI patients, they require prompt, detailed and occasionally, repeated investigations. A joint team approach by health professionals belonging to various medical disciplines, which is strengthened by frequent, informal and honest discussions of a patient's clinical condition, is likely to reduce urological errors in SCI patients.
Resource use data by patient report or hospital records: Do they agree?

Background
          Economic evaluations alongside clinical trials are becoming increasingly common. Cost data are often collected through the use of postal questionnaires; however, the accuracy of this method is uncertain. We compared postal questionnaires with hospital records for collecting data on physiotherapy service use.
        
        
          Methods
          As part of a randomised trial of orthopaedic medicine compared with orthopaedic surgery we collected physiotherapy use data on a group of patients from retrospective postal questionnaires and from hospital records.
        
        
          Results
          315 patients were referred for physiotherapy. Hospital data on attendances was available for 30% (n = 96), compared with 48% (n = 150) of patients completing questionnaire data (95% Cl for difference = 10% to 24%); 19% (n = 59) had data available from both sources. The two methods produced an intraclass correlation coefficient of 0.54 (95% Cl 0.31 to 0.70). However, the two methods produced significantly different estimates of resource use with patient self report recalling a mean of 1.3 extra visits (95% Cl 0.4 to 2.2) compared with hospital records.
        
        
          Conclusions
          Using questionnaires in this study produced data on a greater number of patients compared with examination of hospital records. However, the two data sources did differ in the quantity of physiotherapy used and this should be taken into account in any analysis.
Challenges and Benefits of Modular System Development

This webinar examines the benefits - as well as the mysteries - of modularity when designing a system. The speakers present the basics of modular system development, including when, how, and why to choose modular design. They also highlight Connecticut’s experience with modular development, including the challenges, risks, issues, outcomes, and lessons learned.

This webinar was facilitated by Joyce Rose, a consultant to ICF. The presenters include the following individuals:

Metadata-only record linking to the original dataset. Open original dataset below.
2010 CMHS Uniform Reporting System (URS) Output Tables for Delaware

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
HaploinsufficientBmp4ocular phenotypes include anterior segment dysgenesis with elevated intraocular pressure

Glaucoma is a blinding disease usually associated with high intraocular pressure (IOP). In some families, abnormal anterior segment development contributes to glaucoma. The genes causing anterior segment dysgenesis and glaucoma in most of these families are not identified and the affected developmental processes are poorly understood. Bone morphogenetic proteins (BMPs) participate in various developmental processes. We tested the importance ofBmp4gene dosage for ocular development and developmental glaucoma.
Healthcare Associated Infections - State

The Healthcare-Associated Infections (HAI) measures - state data. These measures are developed by Centers for Disease Control and Prevention (CDC) and collected through the National Healthcare Safety Network (NHSN). They provide information on infections that occur while the patient is in the hospital. These infections can be related to devices, such as central lines and urinary catheters, or spread from patient to patient after contact with an infected person or surface. Many healthcare associated infections can be prevented when the hospitals use CDC-recommended infection control steps.
CMS Program Statistics - Medicare-Medicaid Dual Enrollment

The CMS Program Statistics - Medicare-Medicaid Enrollment tables provide data on characteristics of the Medicare-Medicaid enrollee population. 

For additional information on enrollment, providers, and Medicare use and payment, visit the CMS Program Statistics page.

 

Below is the list of tables:


	MDCR ENROLL AB 40.  Medicare-Medicaid Enrollment (MME):  Total Medicare-Medicaid Enrollees by Type of Eligibility, Yearly Trend
	MDCR ENROLL AB 41.  Medicare-Medicaid Enrollment (MME):  Total Medicare-Medicaid Enrollees by Type of Eligibility and by Demographic Characteristics
	MDCR ENROLL AB 42.  Medicare-Medicaid Enrollment (MME):  Total Medicare-Medicaid Enrollees by Type of Eligibility and Area of Residence
	MDCR ENROLL AB 43.  Medicare-Medicaid Enrollment (MME):  Original Medicare Enrollees by Type of Eligibility, Yearly Trend
	MDCR ENROLL AB 44.  Medicare-Medicaid Enrollment (MME):  Original Medicare Enrollees by Type of Eligibility and by Demographic Characteristics
	MDCR ENROLL AB 45.  Medicare-Medicaid Enrollment (MME):  Original Medicare Enrollees by Type of Eligibility and Area of Residence
	MDCR ENROLL AB 46.  Medicare-Medicaid Enrollment (MME):  Medicare Advantage and Other Health Plan Enrollees by Type of Eligibility, Yearly Trend
	MDCR ENROLL AB 47.  Medicare-Medicaid Enrollment (MME):  Medicare Advantage and Other Health Plan Enrollees by Type of Eligibility and by Demographic Characteristics
	MDCR ENROLL AB 48.  Medicare-Medicaid Enrollment (MME):  Medicare Advantage and Other Health Plan Enrollees by Type of Eligibility and Area of Residence
Bromfenac sodium

Bromfenac Sodium is a prescription eye drop solution used to reduce inflammation and pain in the eye, often after cataract surgery. Manufactured by Alembic Pharmaceuticals Inc., it contains bromfenac sodium at 0.07% strength and is applied topically. This non-steroidal anti-inflammatory drug works by inhibiting cyclooxygenase enzymes. This information was generated using AI and is provided for informational and research purposes only.
Louisiana: 2011-2012 NSDUH

This report presents Louisiana\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
NCHS - Birth Rates for Unmarried Women by Age, Race, and Hispanic Origin: United States

This dataset includes birth rates for unmarried women by age group, race, and Hispanic origin in the United States since 1970. 

Methods for collecting information on marital status changed over the reporting period and have been documented in:

• Ventura SJ, Bachrach CA. Nonmarital childbearing in the United States, 1940–99. National vital statistics reports; vol 48 no 16. Hyattsville, Maryland: National Center for Health Statistics. 2000. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr48/nvs48_16.pdf.
• National Center for Health Statistics. User guide to the 2013 natality public use file. Hyattsville, Maryland: National Center for Health Statistics. 2014. Available from: http://www.cdc.gov/nchs/data_access/VitalStatsOnline.htm.

National data on births by Hispanics origin exclude data for Louisiana, New Hampshire, and Oklahoma in 1989; for New Hampshire and Oklahoma in 1990; for New Hampshire in 1991 and 1992. Information on reporting Hispanic origin is detailed in the Technical Appendix for the 1999 public-use natality data file (see (ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/Nat1999doc.pdf.)

All birth data by race before 1980 are based on race of the child. Starting in 1980, birth data by race are based on race of the mother.
QHP Landscape Instructions PY2023 Dental SHOP

The Dental SHOP Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to employers in the Small Business Health Options Program (SHOP) market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
Chicago: Drug-Related Emergency Department Visits, 2004-2011 - Adverse Reactions

Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving adverse reactions in the Chicago metropolitan area. It includes ED visits in which an adverse health consequence (e.g., side effects or an allergic reaction) resulted when taking prescription drugs, over-the-counter medications, or dietary supplements as prescribed or recommended.  This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Publications Using SAMHSA DataResults from the 2010 National Survey on Drug Use and Health: Mental Health Detailed Tables

This is the report pertaining to mental health from the 2010 National Survey on Drug Use and Health (NSDUH). The report presents national estimates of the prevalence of past year mental disorders and past year mental health service utilization for youths aged 12 to 17 and adults aged 18 or older. Among adults, estimates presented include rates and numbers of persons with any mental illness (AMI), serious mental illness (SMI), suicidal thoughts and behavior, major depressive episode (MDE), treatment for depression (among adults with MDE), and mental health service utilization. Estimates for youths include MDE, treatment for depression (among youths with MDE), and mental health service utilization. Measures related to the co-occurrence of mental disorders with substance use or with substance use disorders also are presented for both adults and youths. Results are provided for age group, gender, race/ethnicity, education level, employment status, poverty level, geographic area, insurance status. Comparisons are made between 2010 and 2002 to 2009.
New Hampshire (NH)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for New Hampshire for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Patent AT-E401524-T1: [Translated] AUTOMATICALLY CLOSING DEVICE FOR FASTENING AN ELEMENT TO A FIXED SUPPORT

The invention relates to a device (10) for fixing an element to a fixed support, comprising an automatically-closing holding collet (11). The collet (11) comprises a main cradle (15) and secondary cradles (16, 17) forming the jaws thereof. The secondary cradles (16, 17) form a central support zone (20), co-operating with the element to be fixed, in order to actuate the automatic closure of said secondary cradles (16, 17). The collet (11) also includes an actuation pin (34) and a dowel (28), comprising two parallel deformable posts (32a, 32b) which define a slot (33). The pin (34) co-operates with the dowel (28) in order to lock the collet (11) in a housing in the fixed support, comprising the insertion of the actuation pin (34) in the slot (33) and the radial expansion of the posts (32a, 32b) during the automatic closure of the secondary cradles (16, 17).
Compound 530708: 5-Bromovaleric acid, 2,7-dimethyloct-7-en-5-yn-4-yl ester

Chemical compound data from PubChem database. IUPAC Name: 2,7-dimethyloct-7-en-5-yn-4-yl 5-bromopentanoate. Molecular Formula: C15H23BrO2. Molecular Weight: 315.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530047: 17alpha-Hydroxyprogesterone, bis(O-methyloxime)

Chemical compound data from PubChem database. IUPAC Name: 3-methoxyimino-17-(N-methoxy-C-methylcarbonimidoyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-ol. Molecular Formula: C23H36N2O3. Molecular Weight: 388.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401330-T1: [Translated] 2,3-OLEFINIC EPOTHILONE DERIVATIVES

The present invention relates to 2,3-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor. The compounds of the invention as 16-membered macrolides having the general structure,which have microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tumor cells or other hyperproliferative cellular disease.
Antibiotics for coughing in general practice: a questionnaire study to quantify and condense the reasons for prescribing

Background
          Antibiotics are being overprescribed in ambulant care, especially for respiratory tract infections (RTIs). Gaining insight into the actual reasons for prescribing remains important for the design of effective strategies to optimise antibiotic prescribing. We aimed to determine items of importance for the antibiotic prescribing decision and to make them operational for an intervention trial.
        
        
          Methods
          A postal questionnaire based upon focus group findings was sent to 316 Flemish general practitioners (GPs). On a verbal rating scale the GPs scored to what extent they consider the questionnaire items in decision making in case of suspected RTI in a coughing patient and how strongly the items support or counter antibiotic treatment. Factor analysis was used to condense the data. The relative importance of the yielded operational factors was assessed using Wilcoxon Matched Pairs test.
        
        
          Results
          59.5% completed the study. Response group characteristics (mean age: 42.8 years; 65.9% men) approximated that of all Flemish GPs. Participants considered all the items included in the questionnaire: always the operational factor 'lung auscultation', often 'whether or not there is something unusual happening' – both medical reasons – and to a lesser extent 'non-medical reasons' (P < 0.001). Non-medical as well as medical reasons support antibiotic treatment, but non-medical reasons to a lesser extent (P < 0.001).
        
        
          Conclusion
          This study quantified, condensed and confirmed the findings of previous focus group research. Practice guidelines and interventions to optimise antibiotic prescribing have to take non-medical reasons into account.
Treatment of achalasia: the short-term response to botulinum toxin injection seems to be independent of any kind of pretreatment

Background
          It has been suggested that intrasphincteric injection of botulinum toxin (BTX) may represent an alternative therapy to balloon dilatation in achalasia. The aim of the present study was to test the effectiveness of botulinum toxin injections in achalasia patients, as assessed using lower oesophageal sphincter pressure (LOSP) and symptom scores, and to compare the response in patients with different types of pretreatment (no previous treatment, balloon dilatation, myotomy, BTX injection).
        
        
          Methods
          Forty patients who presented with symptomatic achalasia were treated with BTX injection (48 injections in 40 patients). Some of the patients had received prior treatment (seven with myotomy, seven with dilatation and eight with BTX). The symptoms were assessed using a global symptom score (0–10), which was evaluated before treatment, 1 week afterwards, and 1 month afterwards. Manometry was also carried out before and after treatment. Three different selections of patients were studied: all patients; untreated patients; and patients with prior BTX, dilatation, or myotomy.
        
        
          Results
          After BTX injection, there was a significant reduction in LOSP (before, 38.2 ± 11.3 mmHg; 1 week after, 20.5 ± 6.9 mmHg; 1 month after, 17.8 ± 6.8 mmHg; P < 0.001). The global symptom score and symptom subscores (dysphagia, regurgitation, chest pain) were significantly decreased after 1 week and 1 month. When the beneficial effects following BTX injection were compared (untreated vs. pretreated), neither changes in LOSP nor beneficial effects on the symptom scores significantly differed. After 6 months, 67.7% of all treated patients were still in symptomatic remission (subgroups: previously untreated patients, 61.5%, n = 26; prior dilatation, 71.4%, n = 7; prior myotomy, 71.4%, n = 7; prior BTX, 73.9%, n = 8).
        
        
          Conclusions
          BTX injection offers an alternative treatment for achalasia which is safe and can be performed in an outpatient setting. The initial response to BTX, in terms of symptom scores and LOSP, appears to be independent of any prior treatment. A number of patients do not adequately respond to balloon dilatation or myotomy, which are the first-line treatment modalities in achalasia patients. BTX injection can be performed in these patients, and symptomatic benefit can be expected in the same percentages as with BTX injection in untreated patients.
Compound 528300: Pyrazine, 2-decyl-3-ethylthio

Chemical compound data from PubChem database. IUPAC Name: 2-decyl-3-ethylsulfanylpyrazine. Molecular Formula: C16H28N2S. Molecular Weight: 280.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399682-T1: [Translated] REAR EXTENSION FOR A MOTOR VEHICLE

A rear-end extension for a motor vehicle, which can be fixed to a rear end cutout on the body of a vehicle with the aid of detachable fixing means is known per se. According to the invention, a dimensionally stable rear-end module is provided, the end contour thereof being adapted to a peripheral edge of the cut out of the body of the vehicle in such a way that the rear-end module can be joined to the rear-end cutout of the body of the vehicle in a peripherally flush manner. The fixing means are adapted to the fixing points, on the vehicle body, of at least one vehicle-body rear-end part provided for closing the cutout of the vehicle body such that the rear-end module can be detachably fixed to the rear-end cutout on the body of the vehicle using fixing points for the vehicle-body rear-end part when the vehicle-body rear-end part is in a remote position. The invention can be used for passenger cars having a steeply inclined rear end.
Caspofungin acetate

Caspofungin Acetate is an antifungal medication used to treat serious fungal infections. It belongs to the echinocandin class and is administered intravenously as a powder that is mixed into a solution. Available in 50 mg and 70 mg vials, it's a prescription drug manufactured by Sandoz Inc. This information was generated using AI and is provided for informational and research purposes only.
2010 CMHS Uniform Reporting System (URS) Output Tables for Louisiana

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 528697: Trimethylsilyl 4,8-bis[(trimethylsilyl)oxy]-2-quinolinecarboxylate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 4,8-bis(trimethylsilyloxy)quinoline-2-carboxylate. Molecular Formula: C19H31NO4Si3. Molecular Weight: 421.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.